Shareholders include UK-listed internet services provider Mail.ru Group and Japan-based financial services group Mitsui own A shares which will have "substantial control" over the company even though Qiwi's regulatory filing said they could be competitors.

Portola said it had raised $317.3m in convertible preferred stock from its investors and $167m in license fees from Biogen, Merck, Novartis, BMS and Pfizer.

Lanxess invested $10m at $28.49 per share as part of BioAmber's $30m series C round.

Company floats 4.75 million shares at $17 each to raise $80.75m.

Marin has set its price range at between $11 and $13 for each of the seven million shares it plans to sell, with a further 1.05 million available if the flotation goes well.

Enanta would have an initial market capitalisation of $252m at $15 per share, according to its regulatory filing.

US-based Silver Spring, backed by Google Ventures, Kleiner Perkins Caufield & Byers and Northgate Capital, has set its IPO range at $16-$18 for 3.7 million shares.

Ambit, formerly known as Aventa Biosciences, has hired investment banks Citigroup and Leerink Swann for its $57.5m initial public offering (IPO) after raising more than $165m.

Globes said other Israeli life sciences companies were also planning their US initial public offering, including Kamada, Alcobra and Home Skinovations.